PharmaTelevision - Sir Michael Rawlins Criticises Excessive Pharma Executive Pay

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Sir Michael Rawlins Criticises Excessive Pharma Executive Pay

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview with Sir Michael Rawlins, the Chairman of NICE, Fintan Walton discusses the financial issues facing pharmaceutical and biotech companies throughout the drug discovery and development process. Following several comments made by Sir Michael Rawlins in the UK national press regarding the pricing of drugs and the executive reward structure within the industry, they discuss the need for radical change in the way drug development proceeds from the regulatory level through to the marketing and pricing of drugs.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The role of NICE.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here live in London. On this show I have Professor Sir Michael Rawlins, who is Chairman of NICE here in the UK. Welcome to the show.

Michael Rawlins:

Thank you.

Fintan Walton:

Michael, National Institute for Health and Clinical Excellence is NICE.

Michael Rawlins:

Yeah.

Fintan Walton:

And is an organization which plays a critical role in both clinical development of drugs and the pricing of drugs in the UK. Could you just outline briefly the specific role that NICE has?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Michael Rawlins

Chairman

Professor Sir Michael Rawlins was appointed Chairman of the National Institute of Health & Clinical Excellence (NICE) after it's founding in 1999. He also holds several other positions such as Chairman of the Advisory Council on the Misuse of Drugs (since 1998), Honorary Professor at the London School of Hygiene and Tropical Medicine and Emeritus Professor at the University of Newcastle upon Tyne. In 1973 Sir Michael Rawlins became the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne, a position he held until 2006. At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust he is a fellow of the Royal Society of Medicine. Between 1987 and 1998 he sat on the Committee on Safety of Medicines as both Chairman and Vice-Chairman. Sir Michael has won several awards such as the Lilly Medal from the British Pharmacological Society, of Amsterdam, the Dixon Medal from the Ulster Medical Society and the Paracelsus Medal from the University of Amsterdam.

NICE

The National Institute for Health and Clinical Excellence ,(NICE) is a Special Health Authority of the NHS responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health in the UK. Founded in 1999 as The National Institute for Health and Clinical Excellence, it merged with the Health Development Agency in 2005 to become NICE as it is today. The organization produces guidance in three areas of health; public health, health technologies and clinical practice and also publishes appraisals of drugs for the NHS based on cost- and clinical-effectiveness. NICE has gained a high profile internationally as a potential role model for the prioritization of health services.